

U.S. NUCLEAR REGULATORY COMMISSION **REGULATORY GUIDE**

OFFICE OF STANDARDS DEVELOPMENT

REGULATORY GUIDE 8.20

APPLICATIONS OF BIOASSAY FOR I-125 AND I-131

A. INTRODUCTION

Section 20.108, "Orders Requiring Furnish-ing of Bioassay Services," of 10 CFR Part 20, "Standards for Protection Against Radiation," indicates that the Nuclear Regulatory Commission (NRC) may incorporate into a license provisions requiring a specific program of bioassay measurements as necessary or desirable to aid in determining the extent of an individual's exposure to concentrations of radioactive material. In certain cases, the requirement of bioassay may also be included in the license by reference to procedures specifying in vivo measurements, measurements of radioactive material in excreta, or both,

This guide provides criteria acceptable to the NRC staff for the development and implementation of a bioassay program for any licensee handling or processing I-125 or I-131. It further provides guidance to such licensees regarding the selection of workers who should participate in a program to detect and measure possible internal radiation exposure. The guide is programmatic in nature and does not deal with measurement techniques and procedures.

B. DISCUSSION

The topics treated in this guide include determinations of (1) whether bioassay should be performed, (2) frequencies of bioassay, (3) who should participate, (4) the actions to take based on bioassay results, and (5) the particular results that should initiate such actions.

For the user's convenience, the following terms are presented with their definitions as used in this guide:

Bioassay-The determination of the kind, quantity or concentration, and location of radioactive material in the human body by direct (in vivo) measurement or by analysis in

USNRC REGULATORY GUIDES

Regulatory Guides are issued to describe and make available to the public methods acceptable to the NRC staff of implementing specific parts of the Commission's regulations, to delineate techniques used by the staff in evaluating specific problems or postulated accidents, or to provide guidance to applicants. Regulatory Guides are not substi-tutes for regulations, and compliance with them is not regulard. Methods and solutions different from those set out in the guides will be acceptable if they provide a basis for the findings requisite to the issuance or continuance of a permit or license by the Commission.

Comments and suggestions for improvements in these guides are encouraged at all times, and guides will be revised, as appropriate, to accommodate comments and to reflect new information or experi-ence. This guide was revised as a result of substantive comments received from the public and additional staff review.

vitro of materials excreted or removed from the body.

Intake-The total quantity of radioactive material entering the body.

In vivo measurements-Measurement of gammaor x-radiation emitted from radioactive material located within the body for the purpose of detecting or estimating the quantity of radioactive material present.

In vitro measurements-Measurement of radioactivity in samples of material excreted from the human body.

C. REGULATORY POSITION

1. Conditions Under Which Bioassay Is Necessary

a. Routine¹ bioassay is necessary when an individual handles in open form unsealed² quantities of radioactive iodine that exceed those shown in Table 1 of this guide. The quantities shown in Table 1 apply to both the quantity handled at any one time or integrated as the total amount of activity introduced into a process by an employee over any 3-month period.

b. When quantities handled in unsealed form are greater than 10% of Table 1 values,

*Lines indicate substantive changes from previous issue.

¹ Routine means here that an individual is assigned on a scheduled and repeatable basis to submitten specimens for bioassay or to report for in vivo measurements. Either radiochemical bioassay of urine or in vivo counting is acceptable to the NRC staff for estimating internal radioactivity burdens or intakes. In some cases, however, a licensee may wish to corroborate estimates from urinalysis data with in vivo determinations. Since there are adequate references in the literature to hely devise bioassay measurements, this guide does not include recommended analytical procedures. Each installation should adopt procedures or obtain services best suited to its own needs.

²See discussion in the footnote to Table 1 of this guide.

Comments should be sent to the Secretary of the Commission, U.S. Nuclear Regulatory Commission, Washington, D.C. 20555, Atten-tion: Docketing and Service Branch.

The guides are issued in the following ten broad divisions:

- 1. Power Reactors
 6. Products

 2. Research and Test Reactors
 7. Transportation

 3. Fuels and Materials Facilities
 8. Occupational Health

 4. Environmental and Siting
 9. Antitrust and Financial Review

 5. Materials and Plant Protection
 10. General

Copies of issued guides may be purchased at the current Government Printing Office price. A subscription service for future guides in spe-cific divisions is available through the Government Printing Office. Information on the subscription service and current GPO prices may be obtained by writing the U.S. Nuclear Regulatory Commission, Washington, D.C. 20535, Attention: Publications Sales Manager.

Revision 1 September 1979 routine bioassay may still be necessary under certain circumstances. A written justification for not performing such measurements should be prepared and recorded for subsequent review during NRC inspections whenever bioassay is not performed and the quantities handled exceed 10% of the levels in Table 1.

c. Except as stated in regulatory position 1.e, bioassay is not required when process quantities handled by a worker are less than 10% of those in Table 1.

d. In nuclear reactor installations, employees should be bioassayed by an in vivo count within 30 days after the end of exposure in work locations where concentrations exceeded, or might have exceeded, $9 \times 10^{-9} \mu \text{Ci/ml}$ averaged over any 40-hour period. Table 1 and regulatory position 4 regarding frequency of bioassays are not applicable to reactor licensees.

e. Special bioassay measurements should be performed to verify the effectiveness of respiratory protection devices and protective clothing. If an individual wearing a respiratory protective device or protective clothing is subjected to a concentration of I-125 or I-131 (in any form) in air such that his or her intake with no protection would have exceeded the limits specified in paragraph 20.103(a)(1) of 10 CFR Part 20,3 bioassays should be performed to determine the resulting actual I-125 or I-131 intake. These special bioassay procedures should also be conducted for personnel wearing respirators if for any reason the I-125 or I-131 concentration in air and the duration of exposure are unknown or cannot be conservatively estimated by calculation.

2. Participation

All workers handling radioactive iodine or sufficiently close to the process so that intake is possible (e.g., within a few meters and in the same room as the worker handling the material) should participate in bioassay programs described in regulatory position 1. 3. Types of Bioassays That Should Be Performed

a. <u>Baseline (preemployment or preopera-</u> tional). Prior to beginning work with radioactive iodine in sufficient quantity that bioassay is specified in regulatory position 1.

b. <u>Routine</u>. At the frequency specified in regulatory position 4.

c. <u>Emergency</u>. As soon as possible after any incident that might cause thyroid uptakes to exceed burdens given in regulatory position 5.a(2), so that actions recommended in regulatory position 5.a(2)(b) can be most effective.

d. <u>Postoperational and with Separation Phys-</u> ical. A bioassay should be performed within 2 weeks of the last possible exposure to I-125 or I-131 when operations are being discontinued or when the worker is terminating activities with potential exposure to these radionuclides.

e. <u>Diagnostic</u>. Followup bioassay should be performed within 2 weeks of any measurements exceeding levels given as action points in regulatory position 5 in order to confirm the initial results and, in the case of a single intake, to allow an estimate of the effective half-life of radioiodine in the thyroid.

4. Frequency

a. Initial Routine. Except in situations, where thyroid burdens may exceed quantities specified in regulatory position 5.a(2), a bioassay sample or measurement should be obtained within 72 hours following entry of an individual into an area where bioassay is performed in accordance with regulatory positions 1 and 2 (but waiting at least 6 hours for distribution of a major part of the iodine to the thyroid⁴) and every 2 weeks or more frequently thereafter as long as the conditions described in regulatory positions 1 and 2 exist. When work with radioactive iodine is on an infrequent basis (less frequently than every 2 weeks), bioassay should be performed within 10 days of the end of the work period during which radioactive iodine was handled (but not sooner than 6 hours unless emergency actions to obtain an early prognosis and thyroid blocking treatment are appropriate⁴).

b. <u>After 3 Months</u>. When a periodic measurement frequency has been selected in accordance with regulatory position 4.a, it may be changed to quarterly if, after 3 months, all the following conditions are met:

(1) The average thyroid burden for each individual working in a given area was

³Multiplying the concentrations given in Appendix B to 10 CFR Fart 20, Table I, Column 1, $5 \ge 10^{-9} \ \mu$ Cl/ml for I-125 (soluble) and 9 $\ge 10^{-9} \ \mu$ Cl/ml for I-131 (soluble), by 6.3 $\ge 10^{-9} \ \mu$ Cl/ml for I-125 (soluble) and 9 $\ge 10^{-9} \ \mu$ Cl/ml for I-131 (soluble), by 6.3 $\ge 10^{-9} \ \mu$ Cl/ml for I-125 and 5.7 $\ \mu$ Cl for I-131, which would give a thyroid dose commitment of about 7.5 rems to a 20-gram thyroid integrated over all future time using effective half-lives of 41.8 days for I-125 and 7.6 days for I-131 and using a quality factor (QF) of I.7 to calculate effective disintegration energy in the case of I-125. (This QF of 1.7 is used for conservatism, even though the International Commission on Radiological Protection (1969) and the National Council on Radiation Protection (1971) have published a QF of 1, because some calculations in more recent scientific literature have suggested the use of QF values higher than 1 for electron or beta energies of 0.03 MeV or less.)

⁴NCRP Report No. 55, "Protection of the Thyroid Gland in the Event of Releases of Radioiodine," National Council on Radiation Protection and Measurements, Washington, D.C., August 1, 1977, p. 21.

less than 0.12 μ Ci of I-125, less than 0.04 μ Ci of I-131, and less than the corresponding proportionate amount⁵ of a mixture of these nuclides during the initial 3-month period:

(2) The quarterly average radioiodine concentration (µCi/ml) in air breathed by any worker (as obtained when measurements of radioiodine concentrations in air are required) does not exceed 25% of the concentration values for "soluble"(s) iodine given in Appendix B to 10 CFR Part 20, Table I, Column 1, (5 x 10⁻⁹ μ Ci/ml for I-125 and 9 x 10⁻⁹ μ Ci/ml for I-131), i.e., 25% of these concentrations multiplied by the total air breathed by an employee at work during one calendar quarter, 6.3 x 10⁸ ml, does not exceed 0.8 μCi of I-125 or 1.4 μCi of I-131. The appropriate proportionate amount⁵ of a mixture of these nuclides should be used as a guide when both I-125 and I-131 are present; and

(3) The working conditions during the 3-month period with respect to the potential for exposure are representative of working conditions during the period in which the quarterly bioassay frequency will be employed, and there is no reasonable expectation that the criteria in regulatory positions 4.b(1) and 4.b(2) above will be exceeded.

c. After Use of Respiratory Protection Devices. Between 6 and 72 hours after respiratory protective devices, suits, hoods, or gloves are used to limit exposure as stated in regulatory position 1.e.

For individuals placed on a quarterly schedule, sampling should be randomly distributed over the quarter but should be done within one week after a procedure involving the handling of I-125 or I-131. This will provide a more representative assessment of exposure conditions

5. Action Points and Corresponding Actions

a. Biweekly or More Frequent Measurements

(1) Whenever the thyroid burden at the time of measurement exceeds 0.12 μ Ci of I-125 or 0.04 μ Ci of I-131, the following actions should be taken:

(a) An investigation of the operations involved, including air and other in-plant surveys, should be carried out to determine the causes of exposure and to evaluate the potential for further exposures.

(b) If the investigation indicates that further work in the area might result in exposure of a worker to concentrations that would cause the limiting intakes established in

⁵See Appendix B to this guide for a description and example of using this condition for mixtures.

§ 20.103 of 10 CFR Part 20 to be exceeded, the licensee should restrict the worker from further exposure until the source of exposure is discovered and corrected.

(c) Corrective actions that will eliminate or lower the potential for further exposures should be implemented.

(d) A repeat bioassay should be taken within 2 weeks of the previous measurement and should be evaluated within 24 hours after measurement in order to confirm the presence of internal radioiodine and to obtain an estimate of its effective half-life for use in estimating dose commitment.

(e) Reports or notification must be provided as required by \$ 20.405, 20.408, and 20.409 of 10 CFR Part 20 or as required by conditions of the license pursuant to \$ 20.108 of 10 CFR Part 20.

(2) If the thyroid burden at any time exceeds 0.5 μ Ci of I-125 or 0.14 μ Ci of I-131, the following actions should be taken:

(a) Carry out all steps described in regulatory position 5.a(1).

(b) As soon as possible, refer the case to appropriate medical consultation for recommendations regarding therapeutic procedures that may be carried out to accelerate removal of radioactive iodine from the body. This should be done within 2-3 hours after exposure when the time of exposure is known so that any prescribed thyroid blocking agent would be effective.⁴

(c) Carry out repeated measurements at approximately 1-week intervals at least until the thyroid burden is less than 0.12 μ Ci of I-125 or 0.04 μ Ci of I-131. If there is a possibility of longer-term compartments containing I-125 or I-131 that require evaluation, continue measurements as long as necessary to ensure that appreciable exposures to these other compartments do not go undetected.

b. Quarterly Measurements. Carry out actions at levels as indicated under regulatory position 5.a(1) and (2). If measurements and surveys indicate an appreciable likelihood that a worker will receive further exposures exceeding the criteria of regulatory positions 4.b(1) and 4.b(2), reinstitute biweekly or more frequent bioassays.

D. IMPLEMENTATION

The purpose of this section is to provide information to applicants and licensees regarding the NRC staff's plans for using this regulatory guide.

Except in those cases in which the applicant or licensee proposes an acceptable alternative method, the staff will use the methods described herein after December 15, 1979, in evaluating the radiation protection programs of licensees who have bioassay requirements

incorporated in their licenses in accordance with § 20.108 of 10 CFR Part 20.

If an applicant or licensee wishes to use the method described in this regulatory guide on or before December 15, 1979, the pertinent portions of the application or the licensee's performance will be evaluated on the basis of this guide.

Table 1

ACTIVITY LEVELS ABOVE WHICH BIOASSAY FOR I-125 OR I-131 IS NECESSARY

	ActivityHandled in Unscaled Form Making Bioassay Necessary*	
Types of Operation	Volatile or Dispersible*	Bound to Nonvolatile Agent*
Processes in open room or bench, with possible escape of iodine from process vessels	1 mCi	10 mCi
Processes with possible escape of iodine carried out within a fume hood of adequate design, face velocity, and performance reliability	10 mCi	100 mCi
Processes carried out within gloveboxes, ordinarily closed, but with possible release of iodine from process and occasional exposure to contaminated box and box leakage	100 mCi	1000 mCi

*Quantities may be considered the cumulative amount in process handled by a worker during a 3-month period; e.g., the Total quantities may be considered the cumulative amount in process handled by a worker during a 3-month period; e.g., the total quantity introduced into a chemical or physical process over a 3-month period, or on one or more occasions in that period, by opening stock reagent containers from which radioactive iodine may escape. Quantities in the right-hand column may be used when it can be shown that activity in process is always chemically bound and processed in such a manner that I-125 or I-131 will remain in nonvolatile form and diluted to concentrations less than 0.1 mCi/mg of manner that I-125 or I-131 will remain in nonvolatile form and diluted to concentrations less than 0.1 mCi/mg of nonvolatile agent. Capsules (such as gelatin capsules given to patients for disgnostic tests) may be considered to contain the radioiodine in nonfree form, and bioassay would not be necessary unless a capsule were inadvertently opened (e.g., drupped and crushed). However, certain compounds where radioiodine is normally bound are known to release radioiodine when the material is in process, and the left-hand column may then be applicable. In those laboratories working only with I-125 in radioismunassay (RIA) kits, the quantities of I-125 are very small and in less volatile forms; thus, bioassay requirements may be judged from the right-hand column. In field operations, where reagent containers are opened outdoors for simple operations such as pouring liquid solutions, the above table does not apply; bioassay should be performed whenever an individual employee handles in open form (e.g., an open bottle or container) more than 50 mCi at any one time. any one time.

Operations involving the routine use of I-125 or I-131 in an open room or bench should be discouraged. Whenever practicable, sealed bottles or containers holding more than 0.1 mCi of I-125 or I-131 should be opened at least initially within hoods having adequate face velocities of 0.5 m/sec or more.

APPENDIX A

SUGGESTED REFERENCES TO ASSIST IN ESTABLISHING A BIOASSAY PROGRAM

In response to public comments, this list of publications is provided to assist the licensee in establishing measurements and administrative procedures for a bioassay program appropriate to his operations. This list is not intended to be exhaustive and does not replace the need for professional assistance in establishing analytical procedures or services.

- American National Standard, ANSI N44.3-1973, "Thyroid Radioiodine Uptake Measurements Using a Neck Phantom," American National Standards Institute, Inc., 1430 Broadway, New York, N.Y. 10018, approved August 24, 1973.
- R. C. Brown, "¹²⁵I Ingestions in Research Personnel," <u>Operational Health</u> <u>Physics</u>, pp. 276-278, 1976, proceedings of the Ninth Midyear Topical Symposium of the Health Physics Society, Denver, Colorado, February 1976 (P. L. Carson, W. R. Hendee, and D. C. Hunt, Eds., Central Rocky Mountain Chapter, Health Physics Society, P.O. Box 3229, Boulder, Colorado 80303, \$15).
- E. J. Browning, K. Banerjee, and W. E. Reisinger, Jr., "Airborne Concentration of I-131 in a Nuclear Medicine Laboratory," J. <u>Nucl. Med.</u>, vol. 19, pp. 1078-1081, 1978.
- 4. J. G. Dare and A. H. Deutchman, "The Decay Scheme of Iodine-125 and Its Relationship to Iodine Bioassay," op. cit., Ref. 2, pp. 250-254.
- B. C. Fasiska, "Radiation Safety Procedures and Contamination Control Practices Involved in High Level I-131 Thyroid Therapy Cases," op. cit., Ref. 2, pp. 287-291.
- A. Gavron and Y. Feige, "Dose Distribution and Maximum Permissible Burden of ¹²⁵I in the Thyroid Gland," <u>Health</u> Physics, vol. 23, pp. 491-499, 1972.
- B. Y. Howard, "Safe Handling of Radioiodinated Solutions," op. cit., Ref. 2, pp. 247-249.
- 8. ICRP Publication 10, "Report of Committee IV on Evaluation of Radiation Doses to Body Tissues from Internal Contamination Due to Occupational Exposure," Recommendations of the International Commission on

Radiological Protection, Pergamon Press, Oxford, p. 17, 1968.

- 9. ICRP Publication 10A, "The Assessment of Internal Contamination Resulting from Recurrent or Prolonged Uptakes," Recommendations of the International Commission on Radiological Protection, Pergamon Press, Oxford, 1969.
- A. L. Orvis, "What Is a 'Reportable' Thyroid Burden?" op. cit., Ref. 2., pp. 268-271.
- P. Plato, A. P. Jacobson, and S. Homan, "In Vivo Thyroid Monitoring for Iodine-131 in the Environment," <u>Int. J. Applied</u> <u>Radiat. and Isotopes</u>, vol. 27, pp. 539-545, 1976.
- Radiological Protection Bulletin 25, "Safe Working with Iodine-125," National Radiological Protection Board, Harwell, Didcot, Oxon, England, pp. 19-20, 1978.
- R. P. Rossi, J. Ovadia, K. Renk, A. S. Johnston, and S. Pinsky, "Radiation Safety Considerations in the Management of Patients Receiving Therapeutic Doses of ¹³¹I," op. cit., Ref. 2, pp. 279-286.
- 14. C. T. Schmidt, "Thyroid Dosimetry of ¹²⁵I and an Instrumental Bioassay Procedure," <u>Program and Abstracts: Twenty-Third Annual Conf. on Bioassay, Environmental, and Analytical Chemistry, IDO-12083, Sept. 15, 16, 1977.</u>
- A. Taylor, J. W. Verba, N. P. Alazraki, and W. C. McCutchen, "Monitoring of I-125 Contamination Using a Portable Scintillation Camera," J. Nucl. Med., vol. 19, pp. 431-432, 1978.
- Technical Reports Series No. 148, "Control of Iodine in the Nuclear Industry," International Atomic Energy Agency, Vienna, 1973.

APPENDIX B

CALCULATION OF ACTION LEVELS FOR MIXTURES OF 1-125 AND 1-131

B.1 Controlling Instantaneous Thyroid Burdens

Regulatory position 4.b(1) is based on controlling the instantaneous amount in the thyroid and is taken as 25% of the maximum permissible organ burden (MPOB) of I-125 or I-131 that would give a dose rate of 0.6 rem/week if continuously present in the thyroid. If a mixture of both nuclides is present in the thyroid and X is the fractional activity that is I-125, a 3-month interval may be resumed when the total activity of I-125 and I-131 is below

$$0.12X + 0.04(1 - X)$$

Example

If the measurements of I-125 and I-131 in a worker's thyroid are 0.10 μ Ci of I-125 and 0.05 μ Ci of I-131, the fractional I-125 activity is

$$\begin{array}{l} X = 0.10/(0.10 + 0.05) \\ = 0.667 \end{array}$$

Then

$$0.12X + 0.04(1 - X) = 0.12(0.66?) + 0.04(0.33) = 0.0932$$

$$Total = 0.10 + 0.05 = 0.15 \ \mu Ci$$

Thus, in this case, the worker involved should remain on the biweekly (or more frequent) schedule and should not be put on the quarterly frequency.

B.2 Controlling Total Intakes

Regulatory position 4.b(2) is based on controlling total intakes⁶ during a quarterly period when air concentration data are available to assess the potential exposure of the worker either to random single intakes or to variable or constant continuous exposures. The quantities of 0.8 μ Ci of I-125 and 1.4 μ Ci of I-131 were obtained by calculating 25% of the total quarterly intakes of 3.2 μ Ci of I-125 or 5.7 μ Ci of I-131 (see footnote 3) that would be inhaled when breathing a total of 5.3 x 10⁸ ml per quarter working at the standard man breathing rate for 40 hours per week for 13 weeks.

Example

If the average quarterly concentrations estimated from air sampled in a worker's breathing zone are 3 x $10^{-9} \mu \text{Ci/ml}$ for I-125 and 5 x $10^{-9} \mu \text{Ci/ml}$ for I-131, the total quarterly intakes are:

3 x
$$10^{-9}$$
 x 6.3 x 10^8 = 1.89 µCi I-125
5 x 10^{-9} x 6.3 x 10^8 = 3.15 µCi I-131

 $Total = 5.04 \mu Ci$

Also, X, the proportion of I-125, is 1.89/5.04 = 0.375

Thus the control level for maintaining biweekly or more frequent bioassay checks is:

$$0.8X + 1.4(1 - X) = 0.8(0.375) + 1.4(1 - 0.375)$$

Total = 1.18 µCi for this mixture.

Since the intake of $5.04 \ \mu Ci$ is greater than 1.18, this employee should stay on the more frequent bioassay schedule.

Note: The numbers of significant digits carried in the above calculations do not imply any given degree of accuracy of measurement. Enough digits are carried to allow following the arithmetic for purposes of the examples.

⁶The limiting total quarterly intakes are in different proportions for I-125 and I-131 than are the MPOBs. This difference is a result of the fact that permissible concentrations are inversely proportional to effective half-lives whereas an MPOB is calculated assuming a constant burden in the organ of concern that is maintained by continuous intake of activity balanced by an equal rate of elimination from the organ.